Myldroх (Meldonium Dihydrate)

Meldonium blocks the synthesis of carnitine, a molecule needed for fatty‑acid transport into mitochondria. This inhibition shifts heart‑muscle energy production from fatty‑acid oxidation toward glucose oxidation, a more oxygen‑efficient pathway, thereby enhancing tolerance to low‑oxygen (ischemic) conditions.

The appropriate dose of Myldroх is set by the prescribing clinician based on the patient’s specific cardiovascular condition, age, renal and hepatic function, and concomitant therapies. No universal dosing schedule is provided; the prescriber tailors therapy to individual needs.

Safety data for Meldonium in pregnancy and lactation are limited. Current guidance advises avoiding Myldroх during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk, and only under close medical supervision.

To order Myldroх, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myldroх (Meldonium) differs from other modulators such as trimetazidine or ranolazine by specifically inhibiting carnitine synthesis, which directly reduces fatty‑acid oxidation. This unique mechanism may offer distinct benefits in patients where oxygen efficiency is a priority, though comparative effectiveness depends on individual clinical scenarios.

Store Myldroх at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Avoid exposing the product to high humidity or extreme heat to maintain its stability and potency.

Myldroх is taken orally, typically as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule (e.g., once or twice daily) is determined by the treating physician based on therapeutic goals.

Serious risks, though rare, include severe allergic reactions such as rash or angioedema, marked hypotension, cardiac arrhythmias, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms like swelling, difficulty breathing, fainting, or jaundice.

Myldroх should be avoided in individuals with known hypersensitivity to Meldonium or any excipients, in patients with uncontrolled severe hypotension, and in those where the risk–benefit ratio is unfavorable, such as certain pregnant or lactating women without clear medical justification.